Tejas Patil, Thoracic Oncologist at University of Colorado Cancer Center, shared a post on X about a paper by Federica Pecci et al. published in Clinical Cancer Research:
“This is a GREAT paper published in Clinical Cancer Research that addresses a KEY question in NSCLC.
What is the optimal 1L therapy for patients with METEx14 NSCLC – TKI or ICI+/-chemo?
Many provocative findings, but two that stood out to me
- Supplemental Table 7: small numbers, but smoking does not appear to be a distinguishing factor between real-world PFS and OS
- No difference in 2L PFS or OS, suggesting that order may be tailored to the clinical situation.”
Title: First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Authors: Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Eleonora Gariazzo, Francesco Mantuano, Edoardo Garbo, Mihaela Aldea, Valentina Santo, Don Gibbons, Hai Tran, Francesco Paoloni, Guilherme Rossato de Almeida, Giulio Metro, Andrea De Giglio, Francesco Gelsomino, Xinan Wang, Marcello Tiseo, Julia Rotow, Andrea Ardizzoni, J. Jack Lee, Mark M. Awad, Alfredo Addeo, Lingzhi Hong, Marcelo V. Negrao, Pasi A. Janne, John V. Heymach, Jianjun Zhang, Biagio Ricciuti, Xiuning Le
You can read the Full Article in Clinical Cancer Research.
More posts featuring Tejas Patil.